...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Journal of dermatological science >Immunohistochemical characterization of cutaneous drug eruptions by STI571.
【24h】

Immunohistochemical characterization of cutaneous drug eruptions by STI571.

机译：STI571对皮肤药疹的免疫组织化学表征。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: STI571, a selective BCR-ABL tyrosine kinase inhibitor, is a promising new drug for chronic myelogenous leukemia (CML). However, the drug has been reported to be associated with adverse cutaneous drug eruptions with high frequency. OBJECTIVE: In this study, the characteristics of the cutaneous drug eruptions by STI571 were investigated. METHODS: The clinical records of 10 patients diagnosed with drug eruption by STI571 were reviewed. We obtained 10 skin biopsy specimens from patients with drug eruption by STI571, 6 from the antibiotics-induced drug eruption group, and 5 from normal skin (control). Immunohistochemical analysis was performed to detect CD4, CD8, CD56, IL-18, IL-1beta and ICAM-1 expression in the cutaneous drug eruption. RESULTS: Seven out of 10 patients had maculopapular exanthema, 2/10 erythema multiforme, 1/10 urticaria. We analyzed the composition of T-lymphocyte subsets from the infiltrates at the STI571-induced drug eruption site in eight patients. Unlike other drug eruptions, the increase in the CD8 expression was statistically significant, especially in the dermoepidermal junction and the upper dermis (P < 0.01). The enhanced expression of IL-18 and IL-1beta was observed as well. In contrast, ICAM-1 was either weakly positive or negative. CONCLUSION: Drug eruption caused by STI571 was mostly expressed as a maculopapular exanthema. The histopathological findings were similar in drug eruption by antibiotics or STI571. Unlike the drug eruptions caused by antibiotics, where the expression of CD4 was dominant, CD8 was dominant in drug eruptions by STI571. The expression of IL-18 and IL-1beta was increased in both groups. This elevation of IL-18 and IL-1beta may assist in understanding the pathogenesis of cutaneous drug eruption.
机译：背景：STI571，一种选择性的BCR-ABL酪氨酸激酶抑制剂，是一种有望用于慢性粒细胞白血病（CML）的新药。但是，据报道该药物与不良的皮肤药物爆发频率高有关。目的：研究STI571引起的皮肤药疹特征。方法：回顾性分析STI571诊断为药疹的10例患者的临床资料。我们从STI571药疹患者中获得了10个皮肤活检标本，抗生素诱导的药疹组中有6个皮肤活检标本，正常皮肤（对照）中有5个皮肤活检标本。进行免疫组织化学分析以检测皮肤药疹中的CD4，CD8，CD56，IL-18，IL-1β和ICAM-1表达。结果：每10例患者中有7例发生黄斑丘疹性皮疹，2/10个多形性红斑，1/10个荨麻疹。我们分析了八名患者在STI571诱导的药疹部位浸润的T淋巴细胞亚群的组成。与其他药物爆发不同，CD8表达的增加在统计学上是显着的，尤其是在真皮表皮交界处和上层真皮中（P <0.01）。还观察到IL-18和IL-1β的表达增强。相反，ICAM-1呈弱阳性或阴性。结论：STI571引起的药疹主要表现为斑丘疹性皮疹。组织病理学发现与抗生素或STI571的药疹相似。与抗生素引起的药物爆发不同，CD4的表达占主导地位，而CD8在STI571的药物爆发中占主导地位。两组中IL-18和IL-1β的表达均增加。 IL-18和IL-1beta的这种升高可能有助于了解皮肤药疹的发病机理。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号